

Characterization, mechanism of action and optimization of activity of a novel peptide-peptoid hybrid against bacterial pathogens involved in canine skin infections

Greco, Ines; Emborg, Agnete; Jana, Bimal; Molchanova, Natalia; Oddo, Alberto; Damborg, Peter; Guardabassi, Luca; Hansen, Paul

Published in:
Scientific Reports

DOI:
[10.1038/s41598-019-39042-3](https://doi.org/10.1038/s41598-019-39042-3)

Publication date:
2019

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Greco, I., Emborg, A., Jana, B., Molchanova, N., Oddo, A., Damborg, P., Guardabassi, L., & Hansen, P. (2019). Characterization, mechanism of action and optimization of activity of a novel peptide-peptoid hybrid against bacterial pathogens involved in canine skin infections. *Scientific Reports*, 9(1), [3679].
<https://doi.org/10.1038/s41598-019-39042-3>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact rucforsk@kb.dk providing details, and we will remove access to the work immediately and investigate your claim.

SCIENTIFIC REPORTS

Corrected: Publisher Correction

OPEN

Characterization, mechanism of action and optimization of activity of a novel peptide-peptoid hybrid against bacterial pathogens involved in canine skin infections

Ines Greco^{1,2}, Agnete Plahn Emborg^{1,3}, Bimal Jana⁴, Natalia Molchanova^{1,5}, Alberto Oddo^{1,6}, Peter Damborg⁴, Luca Guardabassi^{4,7} & Paul R. Hansen¹

Integumentary infections like pyoderma represent the main reason for antimicrobial prescription in dogs. *Staphylococcus pseudintermedius* and *Pseudomonas aeruginosa* are frequently identified in these infections, and both bacteria are challenging to combat due to resistance. To avoid use of important human antibiotics for treatment of animal infections there is a pressing need for novel narrow-spectrum antimicrobial agents in veterinary medicine. Herein, we characterize the *in vitro* activity of the novel peptide-peptoid hybrid B1 against canine isolates of *S. pseudintermedius* and *P. aeruginosa*. B1 showed potent minimum inhibitory concentrations (MICs) against canine *S. pseudintermedius* and *P. aeruginosa* isolates as well rapid killing kinetics. B1 was found to disrupt the membrane integrity and affect cell-wall synthesis in methicillin-resistant *S. pseudintermedius* (MRSP). We generated 28 analogues of B1, showing comparable haemolysis and MICs against MRSP and *P. aeruginosa*. The most active analogues (23, 26) and B1 were tested against a collection of clinical isolates from canine, of which only B1 showed potent activity. Our best compound 26, displayed activity against *P. aeruginosa* and *S. pseudintermedius*, but not the closely related *S. aureus*. This work shows that design of target-specific veterinary antimicrobial agents is possible, even species within a genus, and deserves further exploration.

Staphylococcus pseudintermedius is a commensal bacterium colonizing dog skin and mucosal sites¹, and it is the predominant cause of canine pyoderma and otitis externa². These common infections represent the main reason for antimicrobial prescription in dogs³. Over the last decade, methicillin-resistant *S. pseudintermedius* (MRSP) has been reported worldwide⁴, including sporadic infections in humans in contact with dogs^{5,6}. *Pseudomonas aeruginosa* is another pathogen frequently involved in canine integumentary infections, in particular otitis externa⁷. *P. aeruginosa* is resistant to most antibiotics used in veterinary medicine. The presence of this pathogen and the increasing frequency of multidrug-resistant MRSP⁸, make treatment of dogs with integumentary infections difficult or even impossible in some cases⁹. In light of the few treatment options available against these pathogens, new therapeutic agents are needed, preferably drugs restricted to veterinary use and with a narrow spectrum¹⁰. This would limit their impact on the commensal microbiota¹¹.

¹Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark. ²Present address: Department of Food Science, Faculty of Science, University of Copenhagen, Rolighedsvej 26, 1958, Frederiksberg, Denmark. ³Present address: Novo Nordisk, Brennum Park 1, 3400, Hilleroed, Denmark. ⁴Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Stigbøjlen 4, 1870, Frederiksberg C, Denmark. ⁵Present address: Roskilde University, Department of Science and Environment, 4000, Roskilde, Denmark. ⁶Present address: Novo Nordisk A/S, Krogshøjvej 44, 2820, Bagsværd, Denmark. ⁷Department of Pathobiology and Population Sciences, The Royal Veterinary College, Hawkshead Lane, North Mymms, AL9 7TA, Hatfield, Herts, United Kingdom. Correspondence and requests for materials should be addressed to P.R.H. (email: prh@sund.ku.dk)




Figure 1. Lead compound **B1** and optimized structures **23** and **26**.

In recent years, antimicrobial peptides (AMPs) have attracted considerable interest as alternative anti-infectives¹². AMPs are present in all multicellular organisms as part of their innate immune systems¹³. They show selective toxicity towards bacteria, rapid killing, broad-spectrum antimicrobial activity, and are active at micromolar concentrations or lower¹⁴. Furthermore, they possess immunomodulatory properties such as leukocyte recruitment and suppression of harmful inflammation¹⁵. Most AMPs exhibit their antimicrobial activity by disrupting the bacterial cell membrane; however, intracellular targets have also been reported¹⁶.

The main drawbacks of AMPs as therapeutics are toxicity and susceptibility to proteases¹⁷. Traditionally, these problems are overcome by chemical modification, such as cyclization or design of peptidomimetics, which are stable to proteases¹⁸. We and others have previously investigated antimicrobial *N*-alkylglycines (peptoids)¹⁹, β -peptoids (*N*-alkyl- β -alanine oligomers)²⁰, β -peptides²¹, lysine-based α -peptide/ β -peptoids²², and α/γ *N*-Acylated-*N*-aminoethylpeptides (AApeptides)²³. Some studies have reported activity of peptides and peptidomimetics against veterinary pathogens²⁴. However, only a few of them aimed at the design and optimization of AMPs with activity against *S. pseudintermedius*^{25–28} and canine strains of *P. aeruginosa*²⁹.

The peptide-peptoid hybrid **B1** (Fig. 1) has been previously identified and described as active against one clinical isolate of *S. pseudintermedius* and *P. aeruginosa*, as well as resistant to proteolytic degradation in conditions resembling *in vivo* metabolism³⁰. The aim of the present study was to investigate the antimicrobial activity of **B1** against a large collection of *S. pseudintermedius* and *P. aeruginosa* isolates from canine infections, determine time-kill kinetics and probe the mechanism of action against *S. pseudintermedius*. Furthermore, we designed and tested 28 analogues of **B1** and selected the peptides **23** and **26** (Fig. 1) for their improved selectivity against *S. pseudintermedius* compared to **B1** while retaining comparable activity against *P. aeruginosa*. Next, we aimed to get insight into the antibacterial activity of **B1**, **23** and **26** against other bacterial species causing infections in dogs. Finally, we closely investigated the selectivity of compounds **23** and **26** against *S. pseudintermedius* relative to *S. aureus*. This study demonstrates that design of peptide-based antimicrobials which target specific veterinary bacterial species is possible.

Results

Antimicrobial activity and killing kinetics. Compound **B1** was identified from a combinatorial library. Further evaluation of **B1**'s antimicrobial activity against a panel of 57 *S. pseudintermedius* isolates from canine infections revealed consistently low MICs (2–4 μ g/mL), irrespective of methicillin resistance (Fig. S5, Supplementary Information). Similar MICs (4–8 μ g/mL) were observed for the three *S. aureus* isolates tested (data not shown). Furthermore, MICs of **B1** against a panel of 50 *P. aeruginosa* isolates ranged from 8–16 μ g/mL.

The time-kill kinetic assay showed complete killing of the tested MRSP strain E104 (MIC = 8–16 μ g/mL) in 2 h at $2 \times$ MIC, and in 1 h at $4 \times$ MIC, revealing a rapid concentration-dependent effect (Fig. 2a). A similar but




Figure 2. Time kill kinetics for B1. Time kill kinetics for B1 against (a) MRSP E104 and (a) *P. aeruginosa* 26314. Time kill assays were performed in triplicate and presented as the average of three different samplings.




Figure 3. Effects of B1 and nisin on DNA (a) and cell wall (b) synthesis as measured by macromolecule biosynthesis analysis. Percentages of DNA and cell wall precursors incorporation with respect to unexposed control are presented as average values of two individual measurements.

slightly inferior effect was detected against the clinical strain *P. aeruginosa* 26314, which was killed at 4x MIC in 2 h and at 2x MIC in 24 h (Fig. 2b). Lower concentrations (1x MIC) of B1 did not eliminate the *Pseudomonas* strain but resulted in delayed re-growth (Fig. 2b).

Mode of action of B1 against *S. pseudintermedius* E104. The mode of action of B1 was investigated by studying the effect of sub-inhibitory concentrations of B1 on membrane potential and macromolecule synthesis rate of the MRSP strain E104. The well-characterized antimicrobial nisin was used as a control. Growth curve analysis of B1 at 3 µg/ml showed cell lysis, as indicated by a decrease of OD over time (Fig. S6 Supplemental Material). However, at lower concentrations, B1 resulted in only minor growth inhibition. This is in contrast with nisin, which in addition to cell lysis at MIC concentration (5 µg/ml), significantly retarded growth, also at sub-inhibitory concentrations.

In order to determine if the lysis of MRSP E104 by B1 was due to the inhibition of cell wall biosynthesis, the synthesis rate of cell wall macromolecules was studied at sub-inhibitory concentrations (1.5 µg/ml). In addition, since cationic AMPs have been reported to interact with DNA due to their positive charge and hydrophobicity, the DNA replication was also measured. B1 resulted in a 20% reduction in cell wall synthesis without affecting DNA replication (Fig. 3). Exposure to nisin resulted in 50% inhibition of DNA synthesis (Fig. 3a) and 60% inhibition of cell wall synthesis (Fig. 3b).

To test the immediate effect of a sub-inhibitory concentration of B1 (1.5 µg/ml) on membrane potential, proton motive force (PMF) was measured using DiSC₃(5) (3,3'-Dipropylthiadicarbocyanine Iodide), a fluorescent probe that concentrates in energized membranes and is released in the environment surrounding a cell upon membrane depolarization, thus increasing the intensity of its emission. As expected, no fluorescence increment was observed after nisin treatment (Fig. 4a,b). On the contrary, B1 caused significant membrane depolarization, as indicated by an increased DiSC₃(5) fluorescence emission (Fig. 5a,b). Furthermore, the energy dissipation effect of B1 on the cell at the lysis concentration (1x MIC) was studied by flow cytometry analysis. Cell death (Fig. 5c, P2) and injury (P3) upon B1 exposure was indicated by the high ratio of propidium iodide (PI) staining relative to thiazole orange (TO) staining, whereas unexposed control cells were mainly stained with TO (Fig. 5b). Taken together, our studies indicated that B1 causes membrane depolarization and affects cell-wall synthesis but not DNA-synthesis.




Figure 4. Effects of B1, Carbonyl cyanide *m*-chlorophenylhydrazone (CCCP) or nisin on DiSC3(5) (3,3'-Dipropylthiadicarbocyanine Iodide) fluorescence. Effects of B1, Carbonyl cyanide *m*-chlorophenylhydrazone (CCCP) or nisin on DiSC3(5) (3,3'-Dipropylthiadicarbocyanine Iodide) fluorescence plotted by emission spectra (a) and increment of fluorescence after exposure (b).




Figure 5. Flow cytometry analysis of MRSP E104 exposed to B1. Four different conditions of cells are represented by boxes: P1 (unstained), P2 (dead cells), P3 (injured cells) and P4 (live cells). FL1 and FL3 axis represent green (thiazole orange, TO) and red fluorescence (propidium iodide, PI), respectively. (a) is a dotted plot of unstained cells, (b,c) are TO/PI stained unexposed and B1 exposed cells, respectively.

Analogues of B1. After characterizing B1 as a lead, we proceeded to generate an ensemble of 28 analogues (Table S1, Supplementary Information) in order to develop compounds with specific activity against *S. pseudintermedius* and *P. aeruginosa*, paired with low activity against methicillin-susceptible *Staphylococcus aureus* (MSSA). Compounds 2–29 are analogues of B1 (Fig. 1A). Compounds 2–5 (Table 1) contain L-Lys and peptoid residues. In compound 2, residue 6 (*N*-4-methylbenzylglycine) was replaced with *N*-benzylglycine resembling Phe; in compound 3, residue 4, *N*-butylglycine, was switched with residue 5, Lys, to generate a hydrophobic and cationic cluster. Compounds 4 and 5 are the reversed compounds of 2 and 3.

Compounds 6–13 contain L-lysine and L-amino acids (Leu, Phe, 1-Nal, 2-Nal) instead of the peptoid residues *N*-butylglycine, *N*-1-naphthylmethylglycine and *N*-4-methylbenzylglycine, respectively. In compound 6, peptoid residues have been replaced with the corresponding amino acids and in 7, residue Leu⁴ and residue Lys⁵ have been switched to obtain a hydrophobic and cationic cluster. Compounds 8 and 9 differ from 6 and 7 for the presence of 2- instead of 1-Nal. Compounds 10–13 are the reverse of 6–9. Compounds 14–21 are analogues of 6–13 in which L-Lys residues have been retained and Leu, 1-Nal, 2-Nal and Phe have been replaced by the corresponding D-stereoisomers.

Based on the data for 1–21, we synthesized a second set of compounds (22–29) maintaining three L-Lys at the N-terminus except for 29. Compounds 22–23 are analogues of 9 in which Phe⁶ and Leu⁴ were replaced by Nle and Tyr, respectively. Compound 23 is an analogue of 7 in which Leu⁴ was replaced with Nle. Compounds 25 and 26 are derived from 15, in which D-Phe⁶ and D-Leu⁴ have been replaced by D-Nle and D-Tyr, respectively. Compounds 27 and 28 contain combinations of substitutions introduced in compounds 22–26. Finally, compound 29 is an analogue of 9 in which Lys residues have been replaced by *N*-(4-aminobutyl)glycine.

MICs of the analogues were determined against *S. pseudintermedius* C22963, MSSA (ATCC 29213), and *P. aeruginosa* 26314. The sequence of each analog, the MICs and hemolysis data against red blood cells are reported in Table 1.

ID	Sequence ^a	Minimum Inhibitory Concentration (µg/ml)			Haemolysis (µM)		
		MRSP C22963	MSSA (ATCC 29213)	<i>P. aeruginosa</i> (26314)	EC ₁₀	EC ₅₀	%H 150(µM)
B1	Lys-Lys-(NBu)Gly-Lys-(N1-Nal)Gly-(N4-MeBn)Gly-(N1-Nal)Gly	2–4 ^b	8–16	8–16	64	230	32
2	Lys-Lys-(NBu)Gly-Lys-(N1-Nal)Gly-(NPhe)Gly-(N1-Nal)Gly	4	8–16	32	—	—	<8
3	Lys-Lys-Lys-(NBu)Gly-(N1-Nal)Gly-(NPhe)Gly-(N1-Nal)Gly	4	16	32	—	—	<8
4	(N1-Nal)Gly-(NPhe)Gly-(N1-Nal)Gly-(NBu)Gly-Lys-Lys-Lys	8	16	32	54	—	24
5	(N1-Nal)Gly-(NPhe)Gly-(N1-Nal)Gly-Lys-(NBu)Gly-Lys-Lys	8	16	32	—	—	<8
6	Lys-Lys-Leu-Lys-(1-Nal)Ala-Phe-(1-Nal)Ala	8	32	8	5	58	96
7	Lys-Lys-Lys-Leu-(1-Nal)Ala-Phe-(1-Nal)Ala	8	16	16	8	140	55
8	Lys-Lys-Leu-Lys-(2-Nal)Ala-Phe-(2-Nal)Ala	8	16	32	56	—	34
9	Lys-Lys-Lys-Leu-(2-Nal)Ala-Phe-(2-Nal)Ala	8	16	16	46	—	39
10	(1-Nal)Ala-Phe-(1-Nal)Ala-Lys-Leu-Lys-Lys	8–16	16–32	64	—	—	<8
11	(2-Nal)Ala-Phe-(2-Nal)Ala-Lys-Leu-Lys-Lys	4–8	16	64	—	—	<8
12	(1-Nal)Ala-Phe-(1-Nal)Ala-Leu-Lys-Lys-Lys	16	32	>64	—	—	<8
13	(2-Nal)Ala-Phe-(2-Nal)Ala-Leu-Lys-Lys-Lys	8	32	>64	110	—	15
14	Lys-Lys-leu-Lys-(1-Nal)ala-phe-(1-Nal)ala	4–8	16	16–32	28	128	58
15	Lys-Lys-Lys-leu-(1-Nal)ala-phe-(1-Nal)ala	2	8	8	8	40	88
16	Lys-Lys-Lys-leu-(2-Nal)ala-phe-(2-Nal)ala	2–4	8–16	32	18	118	60
17	Lys-Lys-leu-Lys-(2-Nal)ala-phe-(2-Nal)ala	8	16	32	8	—	40
18	(2-Nal)ala-phe-(2-Nal)ala-leu-Lys-Lys-Lys	16	32–64	>64	—	—	<8
19	(2-Nal)ala-phe-(2-Nal)ala-leu-Lys-Lys-Lys	16	32	>64	—	—	<8
20	(1-Nal)ala-phe-(1-Nal)ala-Lys-leu-Lys-Lys	16	32–64	>64	—	—	<8
21	(1-Nal)ala-phe-(1-Nal)ala-leu-Lys-Lys-Lys	16	32	32	—	—	<8
22	Lys-Lys-Lys-Leu-(2-Nal)Ala-Tyr-(2-Nal)Ala	16	>64	>64	117	—	14
23	Lys-Lys-Lys-Nle-(2-Nal)Ala-Phe-(2-Nal)Ala	2–4	32–64	8	14	104	59
24	Lys-Lys-Lys-Nle-(1-Nal)Ala-Phe-(1-Nal)Ala	16–32	>64	16	3	41	60
25	Lys-Lys-Lys-leu-(1-Nal)ala-tyr-(1-Nal)ala	2–4	32–64	8	38	138	53
26	Lys-Lys-Lys-nle-(1-Nal)ala-phe-(1-Nal)ala	4–8	>64	8	—	63	56
27	Lys-Lys-Lys-Nle-(2-Nal)Ala-Tyr-(2-Nal)Ala	2–4	64	64	3	56	54
28	Lys-Lys-Lys-leu-(2-Nal)ala-tyr-(2-Nal)ala	2–4	32	32	6	50	64
29	NLys-NLys-NLys-Leu-(2-Nal)Ala-Phe-(2-Nal)Ala	4–8	16–32	32	9	—	46

Table 1. Sequence, Minimum Inhibitory Concentration in µg/mL and Haemolysis (µM) for compound B1 and 28 analogs. ^aAll compounds were synthesized as peptide amides and isolated as TFA salts. ^bMRSP strain E104 (MIC = 8–16 µg/mL).

Compounds **2–21** were generally less active than **B1** with MICs of 2–16 µg/mL against *S. pseudintermedius* C22963, 8–64 µg/mL against *S. aureus*, and 8– >64 µg/mL against *P. aeruginosa* 26314. Hemolysis at 150 µM for compounds **2–17** ranged from <8–96% while the reverse sequences **18–21** were not hemolytic.

To further improve selectivity and hemolysis, we synthesized a second set of compounds (**22–29**) maintaining three L-Lys at the N-terminus except for **29**. Five of the compounds featuring three Lys (or Lys-like residues, Fig. 1) at the N-terminus (**23**, **25**, **26**, **27** and **28**) showed 16-fold better activity against the MRSP strain (MIC 2–4 µg/mL) than against the MSSA strain (MIC 32– >64 µg/mL). Furthermore, they showed moderate activity against MRSA USA300 strain FPR3757 (32– >64 µg/mL) (data not shown). In addition, compound **23**, **25** and **26** retained the activity level of **B1** against *P. aeruginosa* (8 µg/mL). The haemolytic values of compounds **22–29** ranged from 46 to 64% at 150 µM except for compound **22** (14%). The two most promising analogues (**23** and **26**) were selected for further studies due to (i) the low MICs observed in MRSP and *P. aeruginosa*, (ii) the relatively higher antimicrobial effect against *S. pseudintermedius* compared to *S. aureus*, and (iii) a moderate to low-level of hemolysis EC₅₀ of 104 µM and 63 µM, respectively (Table 1).

Time-kill experiments of 23 and 26. Time-kill experiments showed that **26** (Fig. 6). was superior to both **B1** and **23** (Fig. 7a) and displayed complete killing of MRSP C22963 within 1 h at only 0.5x MIC. Similarly to **B1**, these two analogues exhibited complete and concentration-dependent killing of the MRSP strain within 2 h at all tested concentrations at or above the MIC. Surprisingly, **23** was not able to completely kill *P. aeruginosa*, even at the highest tested concentration (8x MIC) (Fig. 7b). We also intended to do time-kill curves for **26** against *P. aeruginosa* (MIC = 16 µg/mL). To our disappointment, **26** precipitated after 15 min in the media, and it was not possible to get reproducible results.

Antimicrobial activity of B1, 23 and 26 against a selection of canine pathogens. In order to get further insight into the antimicrobial spectrum of **B1**, **23** and **26**, we tested MICs against a collection of clinical isolates representing other canine pathogens (*Corynebacterium auriscanis*, *Enterococcus faecalis*, *Enterococcus*




Figure 6. Time kill curve of compound 26 against MRSP C22963. Time kill curve of compound **26** against MRSP C22963 at four different concentrations. Time kill assays were performed in triplicate and presented as the average of three different samplings.




Figure 7. Time kill kinetics for 23. Time kill kinetics for 23 against (a) MRSP C22963 and (a) *P. aeruginosa* 26314. Time kill assays were performed in triplicate and presented as the average of three different samplings.

Bacteria	B1	23	26
<i>Acinetobacter baumannii</i> , 27065, 16 D1, dog, wound, 2010	64	64	>64
<i>Corynebacterium auriscanis</i> , 31551, 54 C6, dog, ear, 2013	4	8	32
<i>E. coli</i> , 30235, 23 A6, dog, wound, 2012	64	32	32
<i>Enterococcus faecalis</i> , 27404, 17 C7, dog, wound, 2011	64	>64	64
<i>Enterococcus faecium</i> , 30951, 24 C1, dog, ear, 2013	16	64	>64
<i>Klebsiella pneumoniae</i> , 26233, 11 H5, dog, wound, 2010	>64	>64	>64
<i>Pasteurella canis</i> , 31096, 24 C8, dog, skin, 2013	8	>64	>64
<i>Proteus mirabilis</i> , 25178, 9 A4, dog, ear, 2009	>64	>64	>64
<i>Pseudomonas aeruginosa</i> (26314, 12 C5, dog, urine, 2010).	16	64	>64
<i>Streptococcus canis</i> , 26740-1, 14 H1, dog, ear, 2010	4	16	>64
<i>Staphylococcus aureus</i> , 27266, 16 G9, dog, skin, 2010	8	32	64
<i>Staphylococcus pseudintermedius</i> (22963, 3 B9, dog, 2007).	2	4	4

Table 2. Antimicrobial activity of B1, 23 and 26 against a collection of clinical isolates from canine ($\mu\text{g/mL}$).

faecium, *Streptococcus canis*, *Acinetobacter baumannii*, *Escherichia coli*, *Klebsiella pneumonia*, *Pasteurella canis*, *Proteus mirabilis*) (Table 2). All three compounds showed activity against Gram-positive bacteria with MICs ranging between 2–16 $\mu\text{g/mL}$, except for *Enterococcus* (>64 $\mu\text{g/mL}$). However, **B1**, **23** and **26** were substantially less active against the Gram-negative bacteria with most of the MICs in the range of 32–>64 $\mu\text{g/mL}$, *P. aeruginosa* and *Pasteurella canis* being the only exceptions. For the latter species, the effect varied consistently between **B1**, **23** and **26** (8 $\mu\text{g/mL}$, >64 $\mu\text{g/mL}$ and >64 $\mu\text{g/mL}$, respectively).

Selectivity of 23 and 26 between *S. pseudintermedius* and *S. aureus*. Finally, we tested the selectivity of 23 and 26 against clinical isolates of *S. pseudintermedius* (n = 10) vs *S. aureus* (n = 10) (Table S7, supplemental material). We found that the two compounds were generally more active against *S. pseudintermedius* (2–16 µg/mL) than *S. aureus* (32–>64 µg/mL).

Discussion

The aims of this study were to (i) characterize the antimicrobial activity of the novel peptide-peptoid hybrid **B1** against a large collection of two common dog integumentary pathogens *S. pseudintermedius* and *P. aeruginosa*; (ii) probe the mode of action against *S. pseudintermedius* E104; (iii) conduct a structure-activity study of **B1** involving 28 analogues and identify compounds with potent activity against representative strains of *S. pseudintermedius* and *P. aeruginosa*, paired with weak activity against *S. aureus*; (iv) test the most promising of these analogues (**23** and **26**) as well as **B1** against a broad panel of other canine pathogens; (v) test for selectivity within the *Staphylococcus* genus between *S. pseudintermedius* and *S. aureus*.

B1 showed low MICs against 50 canine *P. aeruginosa* (8–16 µg/mL), 57 *S. pseudintermedius* (2–4 µg/mL). Killing kinetics showed that **B1** kills MRSP and *P. aeruginosa* in less than 30 min at 8 x MIC. Our MIC and time-kill data for MRSP and *P. aeruginosa* are comparable with previous literature reports. Mohamed *et al.* designed and tested synthetic peptides (8 to 16 amino acids) against MSSP and MRSP. The most effective peptides displayed a MIC₅₀ and MIC₉₀ of 1 and 2 µM, respectively²⁵. Molchanova *et al.*²² reported 22 different α-peptide/β-peptoid hybrids containing cationic and hydrophobic residues in a 1:1 ratio that were active against MRSP (2–8 µg/mL) as well as other relevant Gram-positive and Gram-negative bacteria. The same authors also identified fluorinated antimicrobial lysine-based peptidomimetics with activity against methicillin-resistant *S. pseudintermedius*²⁶. Finally, Cabassi and coworkers identified a peptide (AMP2041) with activity against human and animal multidrug resistant *P. aeruginosa* isolates³¹, including strains of canine origin. In a parallel study to the present, we have characterized the *in vitro* pharmacokinetic properties of **B1**, including hemolytic activity and stability to proteases. The measured hemolytic activity of **B1** was 32% at 150 µM and the compound showed only 38% degradation after 24 hours exposure to the mix of protease of bacterial origin Pronase. Furthermore, **B1** was suitable for topical delivery from cream formulation and showed no skin penetration after administration³⁰. These data, combined with our results from the present study, suggest that **B1** may be suitable as antimicrobial for topical treatment of canine superficial pyoderma.

To investigate the mode of action of **B1**, we used the well-characterized clinical MRSP ST71 strain E104 (MIC = 8–16 µg/mL), which is resistant to β-lactams, ciprofloxacin, clindamycin, doxycycline, and trimethoprim/sulfamethoxazole⁸. We found that the primary mode of action of **B1** is on the bacterial membrane and secondarily on cell wall synthesis. However, **B1** has no effect on DNA replication. Membrane activity was supported by a reduction of the initial OD in the growth curve study at 3 µg/mL (Fig. S6, Supplementary information), indicating cell lysis. Furthermore, **B1** caused significant membrane depolarization as seen by an increased DiSC₃(5) fluorescence emission (Fig. 4a,b). We obtained further support for the membrane permeabilization by the rapid cell death observed in the flow cytometry assay (Fig. 5).

The primary mode of action of **B1** is in agreement with the classical membrane-targeting mechanism reported for a number of antimicrobial peptides, e.g. magainin II³² and Cecropin B³³. Besides membrane disruption, AMPs may have intracellular targets as reviewed recently³⁴. These include protein³⁵, DNA³⁶, and cell-wall synthesis³⁷. Here, **B1** reduced cell wall synthesis by 20% (Fig. 3b). A few antimicrobial peptides such as plectasin have been reported to inhibit cell wall synthesis in Gram-positive bacteria. Plectasin targets the bacterial cell wall precursor lipid II as determined by advanced NMR³⁸.

Our finding that **B1** does not affect DNA synthesis (Fig. 3a), is in agreement with literature reports that most AMPs do not have this target. However, some exceptions are known, e.g. indolicidin³⁹. Furthermore, LP5, a compound similar to **B1**, has been reported to inhibit DNA replication and induce SOS response in *S. aureus*⁴⁰. This may be due to a difference in net charge +4 (**B1**) and +6 (**LP5**), respectively.

In the mechanism of action study of **B1**, we used the well-characterized antimicrobial agent nisin as control. This antimicrobial compound used in food preservation interacts with the peptidoglycan precursor molecule lipid II, which leads to membrane depolarization and bacterial cell death⁴¹. The mechanism of nisin has been studied using a plethora of different techniques^{42,43}. In our study, nisin had an inhibitory effect on MRSP growth at sub-lysis concentrations (Fig. S6 Supplementary Information). Simultaneous cell lysis and growth inhibition effects by nisin may be linked to the dual mode of action of this AMP, which encompasses both membrane pore formation and cell wall synthesis inhibition. Exposure to nisin resulted in 60% inhibition of cell wall synthesis, and 50% inhibition of DNA synthesis (Fig. 3a,b). We did not investigate the mechanism of **B1** on *P. aeruginosa*, but a few previous reports on the AMP killing mode of action of *P. aeruginosa* exist: using fluorescence microscopy and field emission scanning electron microscopy, Memariani *et al.* found that the 14-mer AMP PV3, kills bacteria by disrupting the cell membrane⁴⁴. Furthermore, Scocchi and coworkers investigated the mechanism of killing against *P. aeruginosa* strain PAO1 and additional three isolates and observed that Bac7 (1–35) inactivated the target cells by disrupting their cellular membranes⁴⁵.

We synthesized 28 analogues of **B1** by (i) altering the peptoid residues position in the sequence; (ii) substituting peptoid residues for L-amino acids; (iii) modifying the chirality of the amino acid components and/or altering their position in the sequence. Like **B1** and most AMPs, these analogues are cationic and hydrophobic. The rationale for their design is further discussed in results section. Besides *S. pseudintermedius* and *P. aeruginosa*, all the analogues were also tested against MSSA (ATCC 29212). Our two best compounds, **23** and **26**, showed slightly higher MICs (Table 1) against *S. pseudintermedius* (2–4 µg/mL and 4–8 µg/mL respectively) and *P. aeruginosa* (8 µg/mL) compared to **B1** and considerably worse activity against MSSA (32–64 µg/mL, >64 µg/mL, respectively).

Hemolysis at 150 μM is a commonly used parameter in the literature for comparison of antimicrobial peptides or peptidomimetics⁴⁶. The hemolytic activity of **23** and **26** was 59% and 56% at 150 μM , respectively. A variation of the therapeutic index, selectivity index, SI, is often used in the field and is defined as the ratio between the concentration leading to 50% lysis of human erythrocytes and the minimum concentration inhibiting bacterial growth $\text{SI} = (\text{HC}_{50}/\text{MIC})$ for the bacterium being considered⁴⁷. The selectivity indices for MRSP C22963 are: **B1** (82), **23** (37), **26** (11). Typically, selectivity indices are below 100, although higher values have been reported⁴⁸.

The SI values are not a major issue for drugs intended for topical use, since a highly hemolytic compound like the steroid antibiotic fusidic acid is being used for against human skin disorders and canine pathogenic staphylococci⁴⁹. Compound **23** showed slower killing kinetics against MRSP C22963 and *P. aeruginosa* than **B1**, and was not able to eliminate *P. aeruginosa* but resulted in delayed re-growth. Notably, compound **26** was able to kill MRSP C22963 within 1 h at only 0.5x MIC, which was faster than both **B1** and **23** and fully comparable with literature reports²⁵.

We tested the activity of **B1** and the analogues **23** and **26** against a broader range of canine pathogens. They displayed antimicrobial activity (Table 2) against a collection of Gram-positive clinical isolates (2- >64 $\mu\text{g}/\text{mL}$) and less against the Gram-negative isolates (8- >64 $\mu\text{g}/\text{mL}$). Generally, **B1** proved a lot more active than **23** and especially **26** (Table 2). In addition to *S. pseudintermedius*, *S. aureus* and *P. aeruginosa*, we observed increased activity for **B1** (4–16 $\mu\text{g}/\text{mL}$) against other bacteria such as: *Corynebacterium auriscanis* associated with canine otitis externa⁵⁰, *Streptococcus canis* which causes respiratory, cutaneous, genital and urinary infections in various animal species⁵¹, *Pasteurella canis* which is a well-known major pathogen of infections caused by dog bites⁵², and *Enterococcus faecium* which is an important nosocomial pathogen⁵³. However, we observed no significant activity against bacterial isolates belonging to the species *Acinetobacter baumannii*, *Escherichia coli*, *Enterococcus faecalis* and *Klebsiella pneumoniae*.

Having established the antimicrobial spectrum of **23** and **26**, we tested the selectivity of **23** and **26** against clinical isolates of *S. pseudintermedius* (n = 10) vs *S. aureus* (n = 10) (Table S7, supplementary information). We found that the two compounds were generally more active against *S. pseudintermedius* (2- >16 $\mu\text{g}/\text{mL}$) than *S. aureus* (32- >64 $\mu\text{g}/\text{mL}$), especially compound **26**. AMPs with enhanced selectivity against a target bacterial genus have been previously reported⁵⁴ and selectivity within a genus has been observed in few other studies⁵⁵. For example, Guo *et al.* published a peptide, C16G2, which is able of killing *S. mutans* selectively but not closely related streptococcal species. Our finding is significant, as we demonstrated that short amphipathic peptidomimetics can maintain activity against *S. pseudintermedius*, even when their efficacy against *S. aureus* decreases multiple folds. This suggests that the former might be more susceptible to membrane-active agents, or susceptible to a wider range of agents. These observations should aid the design of novel therapeutics for the treatment of *S. pseudintermedius* infections in animals, for which **B1**, **23** and **26** pose as promising lead candidates. The underlying reason for the higher activity of compounds **23** and **26** against *S. pseudintermedius* over *S. aureus* is unknown, but might be related to peptides mechanism of interactions with the bacterial cell envelope. The spatial orientation of amino acid side-chains upon interacting with the bacterial membrane is often fundamental for the activity of AMPs⁵⁶. The compounds **B1**, **23** and **26** all contain seven residues, which is too short to display α -helical structure⁵⁷. Therefore, they most likely form random coils. Furthermore, **26** contains D-amino acids, which are known to disrupt α -helix structure⁵⁸. Finally, the presence of even a single peptoid residue in an α -helix has been reported to result in a significant reduction of the helical content⁵⁶.

Similarities and differences among bacterial membranes of different species are crucial in determining the spectrum of activity of amphipathic AMPs⁵⁹. Since the structure of **B1**, **23** and **26** are closely related, we speculate that the mechanism of action of **23** and **26** is similar to that of **B1**. Compound **B1** is an L-peptide/peptoid hybrid, **23** is a full L-peptide containing non-canonical amino acids, whilst **26** is an L/D-peptide hybrid (Fig. 1). The affinity of antimicrobial peptides for bacterial cells is due to their amphiphilic properties (hydrophobic and positively charged). The interaction with the bacterial membrane is regulated, for both peptides and peptoids, by their hydrophobicity. Also, the presence of peptoid residues in the backbone of **B1** may correspond to a higher structural flexibility and a more cell-penetrating action of **B1**. On the other hand, the peptides **23** and **26** may have a more pronounced membrane-disrupting activity, which may correlate with the faster killing effect observed against *S. pseudintermedius*.

Veterinary medicine needs antimicrobials which are tuned to a veterinary spectrum and are not shared with human medicine. These considerations are in line with the “One Health” view of infectious diseases, which acknowledges that humans and animals share the same pool of bacterial pathogens. Moreover, MRSP has been isolated in humans, highlighting its zoonotic potential and therapeutic challenge⁶⁰. Therefore, it is in the interest of veterinary medicine and public health that novel antimicrobial agents target *P. aeruginosa* and *S. pseudintermedius* in companion animals selectively and not closely related species within a genus, including *S. aureus*.

In this perspective, we have characterized a novel peptide-peptoid hybrid **B1** with antimicrobial activity against both *S. pseudintermedius* and *P. aeruginosa*, the main cause of pyoderma in dogs. A structure-activity study identified two compounds, **23** and **26**, with potent activity against the aforementioned species, paired with poor activity against the closely related *S. aureus*. Our results represent a first step towards the design of peptide-based antimicrobials with a pathogen-targeted spectrum, even within a genus. Such investigation deserves further exploration towards the rationale design of drugs selective for veterinary pathogens.

Materials and Methods

Synthesis of peptides and peptidomimetics. The synthesis of the peptides and peptidomimetics was performed as described by Oddo *et al.*⁶¹. Briefly, peptides were synthesized by Fmoc solid phase peptide synthesis (SPPS). Peptidomimetics were prepared by a combination of the above and sub-monomer peptoid synthesis. Following TFA-cleavage, precipitation in ether and lyophilisation, the compounds were purified (>95%) by preparative HPLC and the purity was determined through analytical HPLC. The identity of each compound

was verified by MALDI-TOF-MS. The compounds used in this study are shown in Supplementary Information (Table S1).

Antimicrobial susceptibility testing. Activity of B1 was tested on 50 *P. aeruginosa* isolates and 57 *S. pseudintermedius* isolates (including 7 MRSP) that had been isolated in the diagnostic laboratory Sund Vet Diagnostik (University of Copenhagen) from various infections in dogs between 2009 and 2011. Representative MRSP (C22963), MSSA, and *P. aeruginosa* (26314) were used for testing the first set of B1 analogues.

For antibacterial spectrum the following strains were used: *Corynebacterium auriscanis*, 31551, (54 C6, dog, ear, 2013); *Enterococcus faecalis*, 27404, (17 C7, dog, wound, 2011); *Enterococcus faecium*, 30951, (24 C1, dog, ear, 2013); *Streptococcus canis*, 26740-1, (14 H1, dog, ear, 2010); *Staphylococcus aureus*, 27266, (16 G9, dog, skin, 2010); *Staphylococcus aureus*, 27266, (16 G9, dog, skin, 2010); *Staphylococcus pseudintermedius* 22963, (3 B9, dog, 2007); *Acinetobacter baumannii*, 27065, (16 D1, dog, wound, 2010); *E. coli*, 30235, 23 A6, dog, wound, 2012; *Klebsiella pneumoniae*, 26233, (11 H5, dog, wound, 2010); *Pasteurella canis*, 31096, (24 C8, dog, skin, 2013); *Proteus mirabilis*, 25178, (9 A4, dog, ear, 2009); *Pseudomonas aeruginosa* 26314, 12 C5, dog, urine, 2010).

For testing the selectivity of 23 and 26 against clinical isolates of *S. pseudintermedius* vs *S. aureus* the following strains were used.

S. aureus strains. 25054, (8 G6, dog, wound, 2009); 27266, (16 G9, dog, skin, 2010 also used in exp above); 28264, (20 B1, dog, wound, 2011); 30935, (24 B9, dog, joint, 2013); 36968, (61 A9, dog, wound, 2016); 37595, (65 D2, dog, joint, 2016); 37708-2, (66 C6, dog, skin, 2016); 38200, (68 E9, dog, skin, 2016); 38565-1, (70 A5, dog, skin, 2017); 38841, (70 G5, dog, urine, 2017).

S. pseudintermedius strains. 26071, (11 E5, dog, skin, 2009); 26092-2, (11 E4, dog, skin, 2009); 26959, (15 F8, dog, wound, 2010); 27364, (17 A7, dog, wound, 2011); 27382, (17 B8, dog, ear, 2011); 27382, (17 B8, dog, ear, 2011); 31524, (54 C3, dog, ear, 2013); 33228, (55 E2, dog, skin, 2014); 35890, (59 B8, dog, ear, 2015); 37526-1, (65 B4, dog, skin, 2016); 37535-1, (65 B6, dog, skin, 2016); 37535-1, (65 B6, dog, skin, 2016); 38637, (70 C3, dog, wound 2017); 38820, (70 F9, dog, urine 2017).

MIC determination was performed by broth microdilution according to the Clinical and Laboratory Standard Institute (CLSI, M31-A3, 2008)⁶². In brief, each bacterial strain was diluted to concentration of 5×10^5 CFU/mL in Mueller Hinton broth II (MHB II) media (Oxoid) and added to a two-fold serial dilution of peptides and peptide-peptoid hybrids concentrations ranging from 1 to 64 µg/ml in 96-well plates (Nunc Internationals, Rochester, NY). The MICs were determined as a lowest concentration showing no visible growth after incubation for 18 hours at 37 °C. Experiments were performed in triplicates on two different days.

Time kill curves. Time kill assays were performed in triplicate, meaning that every value is the average of three different samplings. Time-kill kinetic assays were performed using *P. aeruginosa* (26314), MRSP E104 and/or MRSP C22963 to determine the cell killing activity of B1 and two of its most promising analogues (compounds 23 and 26) based on prior antimicrobial susceptibility testing. The method reported by Blondeau *et al.*⁶³ was followed with minor modifications. Briefly, the assay was performed in MHB II with concentrations corresponding to 0.5, 1, 2 and 4 times the MIC of the strain. After 0, 15, 30, 60, 120, 180 and 300 min of growth, 100 µL aliquots were collected and 10-fold serially diluted. Twenty µL of cell suspension from each dilution were spotted in triplicate on blood agar plates followed by 16–18 h incubation at 37 °C and determination of colony forming units (CFU).

Haemolytic activity. The EC₁₀ (10% maximal effective concentration), EC₅₀ (half maximal effective concentration) values and the percentage of haemolysis at 150 µM were determined for all compounds as previously described⁶⁴. Briefly, two-fold serial dilutions (2.35 to 150 µM) of compounds in phosphate buffer saline (PBS) were mixed with equal volume of 0.5% v/v suspension of fresh human red blood cells (RBC) in the same buffer. After 1 h incubation at 37 °C, plates were centrifuged and aliquots of the supernatants were transferred to clear 96-well plates. Absorbance at 414 nm was measured and normalized using a negative (PBS, 0%) and a positive (melittin, 100%) control. The EC₁₀ and EC₅₀ are concentrations at which 10% and 50% of RBC were lysed, respectively, as interpolated graphically by the y-axis intersection of the plotted data.

Macromolecule biosynthesis rate. Macromolecule biosynthesis rate was measured in MRSP E104 following a protocol adapted from Ling *et al.*⁶⁵. Briefly, E104 overnight culture was sub-cultured 1:100 in MHB II and grown up to OD 0.2 at 600 nm. Cells were pelleted down by centrifugation and resuspended in fresh medium followed by incubation for 20 min with B1 or nisin at 1.5 µg/ml and 1.25 µg/ml, respectively, and radiolabeled precursor: (50 µCi) 3H-Thymidine (PerkinElmer) and (5 µCi) 3H-glucosamine hydrochloride per ml for DNA and cell wall, respectively. A positive control without antimicrobial was maintained. After incubation, samples were precipitated with equal volume of cold 30% TCA (Sigma) on ice. Precipitates were filtered on a membrane filter and subsequently subjected to two washes of cold 15% TCA and two washes of cold water using vacuum manifold. Subsequently, filters were air dried overnight and then transferred to 10 ml scintillation vials. Finally, scintillation fluid (3 ml) was added to each vial and ³H count was taken in Beckman Coulter LS6500 liquid scintillation counter for one minute. The radioactive counts of the control samples were considered to have 100% precursor incorporation and macromolecule synthesis. The percentage rates of the antimicrobial-exposed samples were calculated accordingly. Each experiment was performed with replicates and the average rates of incorporation were plotted.

DiSC3(5) fluorescence-based membrane potential study. Freshly sub-cultured E104 cells were labelled with 1 μ M 3,3-Dipropylthiadicarbocyanine iodide [DiSC3(5)] (Sigma) in MHB II. The fluorescence spectra of labelled cells were plotted in the LS50B luminescence spectrometer (PerkinElmer) at excitation/emission wavelengths 546 nm/573 nm using time drive application of FLWINLAB software. After reading an initial stable emission spectra of DiSC3(5), labelled cells were treated with B1 or nisin or protonophore CCCP at 1, 1.5 and 1.25 μ g/ml, respectively and the change of fluorescence over time was recorded. The increment of DiSC3(5) fluorescence upon addition of antimicrobials or CCCP (FUafter-treatment – FUbefore-treatment) was plotted. This experiment was performed twice and each time with two technical replicates.

Flow cytometry analysis of antimicrobial-exposed cells. Freshly grown cultures (OD 0.2 at 600 nm) of MRSP E104 were exposed to 3 μ g/ml of B1 or 2.5 μ g/ml of nisin for 1 h and diluted 1:10 in flow cytometry analysis buffer (PBS supplemented with 1 mM EDTA, 0.01% Tween 20 and filtered by 0.22 μ m membrane). Diluted cells were stained with 420 nM thiazole orange (TO, Sigma) and 48 μ M propidium iodide (PI, Sigma) and analysed using BD ACCURI C6 flow cytometer (BD Biosciences). Unstained cells were used as negative control. Finally, the differentially labelled bacterial populations in antimicrobial-exposed cultures were plotted under FL3(red)/FL1(green) axis using the instrument's software and categorised into four different conditions: P1 (unstained), P2 (dead cells), P3 (injured cells) and P4 (live cells).

References

1. Peacock, S. J. & Paterson, G. K. In *Annual Review of Biochemistry*, Vol 84 Vol. 84 *Annual Review of Biochemistry* (ed R. D. Kornberg) 577–601 (2015).
2. Morell, E. A. & Balkin, D. M. Methicillin-Resistant *Staphylococcus Aureus*: A Pervasive Pathogen Highlights the Need for New Antimicrobial Development. *The Yale Journal of Biology and Medicine* **83**, 223–233 (2010).
3. Weese, J. S. & Van Duijkeren, E. Methicillin-resistant *Staphylococcus aureus* and *Staphylococcus pseudintermedius* in veterinary medicine. *Veterinary Microbiology* **140**, 418–429, <https://doi.org/10.1016/j.vetmic.2009.01.039> (2010).
4. Harrison, E. M. *et al.* A Shared Population of Epidemic Methicillin-Resistant *Staphylococcus aureus* 15 Circulates in Humans and Companion Animals. *mBio* **5**, <https://doi.org/10.1128/mBio.00985-13> (2014).
5. Gomez-Sanz, E., Torres, C., Lozano, C. & Zarazaga, M. High diversity of *Staphylococcus aureus* and *Staphylococcus pseudintermedius* lineages and toxigenic traits in healthy pet-owning household members. Underestimating normal household contact? *Comparative Immunology Microbiology and Infectious Diseases* **36**, 83–94, <https://doi.org/10.1016/j.cimid.2012.10.001> (2013).
6. Stegmann, R., Burnens, A., Maranta, C. A. & Perreten, V. Human infection associated with methicillin-resistant *Staphylococcus pseudintermedius* ST71. *Journal of Antimicrobial Chemotherapy* **65**, 2047–2048, <https://doi.org/10.1093/jac/dkq241> (2010).
7. Goodwin, J. L. & McCamley, R. N. Otitis-Externa Associated With *Pseudomonas-Aeruginosa* Infection. *Veterinary Record* **103**, 343–343 (1978).
8. Brochmann, R. P., Helmfriid, A., Jana, B., Magnowska, Z. & Guardabassi, L. Antimicrobial synergy between carprofen and doxycycline against methicillin-resistant *Staphylococcus pseudintermedius* ST71. *BMC Veterinary Research* **12**, 126, <https://doi.org/10.1186/s12917-016-0751-3> (2016).
9. Graveland, H., Duim, B., van Duijkeren, E., Heederik, D. & Wagenaar, J. A. Livestock-associated methicillin-resistant *Staphylococcus aureus* in animals and humans. *International Journal of Medical Microbiology* **301**, 630–634, <https://doi.org/10.1016/j.ijmm.2011.09.004> (2011).
10. Paul, N. C., Bärgerman, S. C., Moodley, A., Nielsen, S. S. & Guardabassi, L. *Staphylococcus pseudintermedius* colonization patterns and strain diversity in healthy dogs: A cross-sectional and longitudinal study. *Veterinary Microbiology* **160**, 420–427, <https://doi.org/10.1016/j.vetmic.2012.06.012> (2012).
11. Collignon, P. Antibiotic resistance: are we all doomed? *Internal Medicine Journal* **45**, 1109–1115, <https://doi.org/10.1111/imj.12902> (2015).
12. Mercer, D. K. & O'Neil, D. A. Peptides as the next generation of anti-infectives. *Future Medicinal Chemistry* **5**, 315–337, <https://doi.org/10.4155/fmc.12.213> (2013).
13. Zasloff, M. Antimicrobial peptides of multicellular organisms. *Nature* **415**, 389–395 (2002).
14. Hancock, R. Cationic peptides: effectors in innate immunity and novel antimicrobials. *Lancet Infect Dis* **1**, 156–164 (2001).
15. Pasupuleti, M., Schmidtchen, A. & Malmsten, M. Antimicrobial peptides: key components of the innate immune system. *Critical Reviews in Biotechnology* **32**, 143–171, <https://doi.org/10.3109/07388551.2011.594423> (2012).
16. Haney, E. F., Mansour, S. C. & Hancock, R. E. W. In *Antimicrobial Peptides: Methods and Protocols* (ed Paul R. Hansen) 3–22 (Springer New York, 2011).
17. Fosgerau, K. & Hoffmann, T. Peptide therapeutics: current status and future directions. *Drug Discovery Today* **20**, 122–128, <https://doi.org/10.1016/j.drudis.2014.10.003> (2015).
18. Molchanova, N., Hansen, P. R. & Franzky, H. Advances in Development of Antimicrobial Peptidomimetics as Potential Drugs. *Molecules* **22**, <https://doi.org/10.3390/molecules22091430> (2017).
19. Lee, J. *et al.* Effect of side chain hydrophobicity and cationic charge on antimicrobial activity and cytotoxicity of helical peptoids. *Bioorganic & Medicinal Chemistry Letters* **28**, 170–173, <https://doi.org/10.1016/j.bmcl.2017.11.034> (2018).
20. Hamper, B. C., Kolodziej, S. A., Scatez, A. M., Smith, R. G. & Cortez, E. Solid phase synthesis of b-peptoids: N-substituted b-aminopropionic Acid Oligomers. *J. Org. Chem.* **63**, 708–718 (1998).
21. Liu, D. & DeGrado, W. De novo design, synthesis, and characterization of antimicrobial beta-peptides. *J Am Chem Soc.* **123**, 7553–7559 (2001).
22. Molchanova, N., Hansen, P. R., Damborg, P., Nielsen, H. M. & Franzky, H. Lysine-Based α -peptide/ β -peptoid peptidomimetics: Influence of hydrophobicity, fluorination and distribution of cationic charge on antimicrobial activity and cytotoxicity. *ChemMedChem* **20**, 312–318, <https://doi.org/10.1002/cmdc.201600553> (2017).
23. Li, Y. *et al.* Short Antimicrobial Lipo- α/γ -AA Hybrid Peptides. *ChemBioChem* **15**, 2275–2280, <https://doi.org/10.1002/cbic.201402264> (2014).
24. Santoro, D. & Maddox, C. W. Canine antimicrobial peptides are effective against resistant bacteria and yeasts. *Veterinary Dermatology* **25**, 35–e12, <https://doi.org/10.1111/vde.12091> (2014).
25. Mohamed, M. F., Hammac, G. K., Guptill, L. & Seleem, M. N. Antibacterial Activity of Novel Cationic Peptides against Clinical Isolates of Multi-Drug Resistant *Staphylococcus pseudintermedius* from Infected Dogs. *PLoS One* **9**, e116259, <https://doi.org/10.1371/journal.pone.0116259> (2014).
26. Molchanova, N., Hansen, P., Damborg, P. & Franzky, H. Fluorinated antimicrobial lysine-based peptidomimetics with activity against methicillin-resistant *Staphylococcus pseudintermedius*. *J. Peptide Sci.*, <https://doi.org/10.1002/psc.3098> (2018).

27. Fazakerley, J., Crossley, J., McEwan, N., Carter, S. & Nuttall, T. In vitro antimicrobial efficacy of β -defensin 3 against *Staphylococcus pseudintermedius* isolates from healthy and atopic canine skin. *Vet Dermatol.* **21**(5), 463–468 (2010).
28. Itoh, H. *et al.* Total Synthesis and Biological Mode of Action of WAP-8294A2: A Menquinone-Targeting Antibiotic. *The Journal of Organic Chemistry* **83**, 6924–6935, <https://doi.org/10.1021/acs.joc.7b02318> (2017).
29. Cabassi, C. S. *et al.* Activity of AMP2041 against human and animal multidrug resistant *Pseudomonas aeruginosa* clinical isolates. *Annals of Clinical Microbiology and Antimicrobials* **16**, 17, <https://doi.org/10.1186/s12941-017-0193-1> (2017).
30. Greco, I. *et al.* In Vitro ADME Properties of Two Novel Antimicrobial Peptoid-Based Compounds as Potential Agents against Canine Pyoderma. *Molecules* **23**, 630 (2018).
31. Cabassi, C. S. *et al.* Broad-spectrum activity of a novel antibiotic peptide against multidrug-resistant veterinary isolates. *The Veterinary Journal*. <https://doi.org/10.1016/j.tvjl.2013.08.020> (2013).
32. Matsuzaki, K. Control of cell selectivity of antimicrobial peptides. *Biochimica et Biophysica Acta (BBA) - Biomembranes* **1788**, 1687–1692 (2009).
33. Wang, W., Smith, D. K., Moulding, K. & Chen, H. M. The Dependence of Membrane Permeability by the Antibacterial Peptide Cecropin B and Its Analogs, CB-1 and CB-3, on Liposomes of Different Composition. *J. Biol. Chem.* **273**, 27438–27448 (1998).
34. Le, C. F., Fang, C. M. & Sekaran, S. D. Intracellular Targeting Mechanisms by Antimicrobial Peptides. *Antimicrobial Agents and Chemotherapy* **61**, <https://doi.org/10.1128/aac.02340-16> (2017).
35. Graf, M. *et al.* Proline-rich antimicrobial peptides targeting protein synthesis. *Natural Product Reports* **34**, 702–711, <https://doi.org/10.1039/C7NP00020K> (2017).
36. Amiche, M., Seon, A. A., Pierre, T. N. & Nicolas, P. The dermaseptin precursors: a protein family with a common preproregion and a variable C-terminal antimicrobial domain. *FEBS Letters* **456**, 352–356 (1999).
37. Chatterjee, C., Paul, M., Xie, L. & van der Donk, W. A. Biosynthesis and Mode of Action of Lantibiotics. *Chemical Reviews* **105**, 633–684, <https://doi.org/10.1021/cr030105v> (2005).
38. Schneider, T. *et al.* Plectasin, a Fungal Defensin, Targets the Bacterial Cell Wall Precursor Lipid II. *Science* **328**, 1168–1172, <https://doi.org/10.1126/science.1185723> (2010).
39. Subbalakshmi, C. & Sitaram, N. Mechanism of antimicrobial action of indolicidin. *Fems Microbiology Letters* **160**, 91–96, <https://doi.org/10.1111/j.1574-6968.1998.tb12896.x> (1998).
40. Gottschalk, S. *et al.* The antimicrobial lysine-peptoid hybrid LP5 inhibits DNA replication and induces the SOS response in *Staphylococcus aureus*. *BMC microbiology* **13**, 192, <https://doi.org/10.1186/1471-2180-13-192> (2013).
41. 't Hart, P., Oppedijk, S. F., Breukink, E. & Martin, N. I. New Insights into Nisin's Antibacterial Mechanism Revealed by Binding Studies with Synthetic Lipid II Analogues. *Biochemistry* **55**, 232–237, <https://doi.org/10.1021/acs.biochem.5b01173> (2016).
42. Hsu, S.-T. D. *et al.* The nisin–lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. *Nature Structural & Molecular Biology* **11**, 963, 10.1038/nsmb830, <https://www.nature.com/articles/nsmb830#supplementary-information> (2004).
43. Breukink, E. *et al.* Use of the Cell Wall Precursor Lipid II by a Pore-Forming Peptide Antibiotic. *Science* **286**, 2361 (1999).
44. Memariani, H. *et al.* Mechanism of action and *in vitro* activity of short hybrid antimicrobial peptide PV3 against *Pseudomonas aeruginosa*. *Biochemical and Biophysical Research Communications* **479**, 103–108, <https://doi.org/10.1016/j.bbrc.2016.09.045> (2016).
45. Runti, G. *et al.* The Mechanism of Killing by the Proline-Rich Peptide Bac7(1–35) against Clinical Strains of *Pseudomonas aeruginosa* Differs from That against Other Gram-Negative Bacteria. *Antimicrobial Agents and Chemotherapy* **61**, <https://doi.org/10.1128/aac.01660-16> (2017).
46. Soler, M. *et al.* Identification of BP16 as a non-toxic cell-penetrating peptide with highly efficient drug delivery properties. *Organic & Biomolecular Chemistry* **12**, 1652–1663, <https://doi.org/10.1039/C3OB42422G> (2014).
47. Ilić, N. *et al.* Selective antimicrobial activity and mode of action of adeptins, glycine-rich peptide antibiotics based on anuran antimicrobial peptide sequences. *Biochimica et Biophysica Acta (BBA) - Biomembranes* **1004**–**1012**, 2013, <https://doi.org/10.1016/j.bbmem.2012.11.017> (2012).
48. Jahnson, R. D. *et al.* Tailoring Cytotoxicity of Antimicrobial Peptidomimetics with High Activity against Multidrug-Resistant *Escherichia coli*. *Journal of Medicinal Chemistry* **57**, 2864–2873, <https://doi.org/10.1021/jm401335p> (2014).
49. Frosini, S. M., Bond, R., Loeffler, A. & Larner, J. Opportunities for topical antimicrobial therapy: permeation of canine skin by fusidic acid. *Bmc Veterinary Research* **13**, <https://doi.org/10.1186/s12917-017-1270-6> (2017).
50. Aalbaek, B. *et al.* Corynebacteria associated with canine otitis externa. *Vet Microbiol* **145**, 292–298, <https://doi.org/10.1016/j.vetmic.2010.03.032> (2010).
51. Galperine, T. *et al.* *Streptococcus canis* infections in humans: Retrospective study of 54 patients. *Journal of Infection* **55**, 23–26, <https://doi.org/10.1016/j.jinf.2006.12.013> (2007).
52. Kim, B., Pai, H., Lee, K. H. & Lee, Y. Identification of *Pasteurella canis* in a Soft Tissue Infection Caused by a Dog Bite: The First Report in Korea. *Annals of Laboratory Medicine* **36**, 617–619, <https://doi.org/10.3343/alm.2016.36.6.617> (2016).
53. Tremblay, C. L., Charlebois, A., Masson, L. & Archambault, M. Characterization of hospital-associated lineages of ampicillin-resistant *Enterococcus faecium* from clinical cases in dogs and humans. *Frontiers in Microbiology* **4**, <https://doi.org/10.3389/fmicb.2013.00245> (2013).
54. Eckert, R. *et al.* Adding selectivity to antimicrobial peptides: Rational design of a multidomain peptide against *Pseudomonas* spp. *Antimicrobial Agents and Chemotherapy* **50**, 1480–1488, <https://doi.org/10.1128/aac.50.4.1480-1488.2006> (2006).
55. Guo, L. H. *et al.* Precision-guided antimicrobial peptide as a targeted modulator of human microbial ecology. *Proceedings of the National Academy of Sciences of the United States of America* **112**, 7569–7574, <https://doi.org/10.1073/pnas.1506207112> (2015).
56. Uggerhøj, L. E., Munk, J. K., Hansen, P. R., Güntert, P. & Wimmer, R. Structural features of peptoid–peptide hybrids in lipid–water interfaces. *FEBS Letters* **588**, 3291–3297, <https://doi.org/10.1016/j.febslet.2014.07.016> (2014).
57. Manning, M. C., Illangasekare, M. & Woody, W. R. Circular dichroism studies of distorted α -helices, twisted β -sheets, and β -turns. *Biophysical Chemistry* **31**, 77–86, [https://doi.org/10.1016/0301-4622\(88\)80011-5](https://doi.org/10.1016/0301-4622(88)80011-5) (1988).
58. Grieco, P. *et al.* The effect of d-amino acid substitution on the selectivity of temporin L towards target cells: Identification of a potent anti-Candida peptide. *Biochimica et Biophysica Acta (BBA) - Biomembranes* **1828**, 652–660, <https://doi.org/10.1016/j.bbmem.2012.08.027> (2013).
59. Matsuzaki, K. Why and how are peptide–lipid interactions utilized for self defence? *Biochem Soc. Trans.* **29**, 598–601 (2001).
60. Pomba, C. *et al.* Public health risk of antimicrobial resistance transfer from companion animals. *Journal of Antimicrobial Chemotherapy* **72**, 957–968, <https://doi.org/10.1093/jac/dkw481> (2017).
61. Oddo, A. *et al.* An all-D amphipathic undecapeptide shows promising activity against colistin-resistant strains of *Acinetobacter baumannii* and a dual mode of action. *Antimicrobial Agents and Chemotherapy* **60**, 592–599, <https://doi.org/10.1128/aac.01966-15> (2016).
62. Standards, N. C. f. C. L. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Approved standard (2012).
63. Blondeau, J. M., Borsos, S., Blondeau, L. D. & Blondeau, B. J. *In vitro* killing of *Escherichia coli*, *Staphylococcus pseudintermedius* and *Pseudomonas aeruginosa* by enrofloxacin in combination with its active metabolite ciprofloxacin using clinically relevant drug concentrations in the dog and cat. *Veterinary Microbiology* **155**, 284–290, <https://doi.org/10.1016/j.vetmic.2011.08.015> (2012).

64. Munk, J. K., Ritz, C., Flidner, F. P., Frimodt-Møller, N. & Hansen, P. R. Novel method to identify the optimal antimicrobial peptide in a combination matrix using anoplins as an example. *Antimicrob Agents Chemother* **58**, 1063–1070, <https://doi.org/10.1128/aac.02369-13> (2014).
65. Ling, L. L. *et al.* A new antibiotic kills pathogens without detectable resistance. *Nature* **517**, 455–459, 10.1038/nature14098, <http://www.nature.com/nature/journal/v517/n7535/abs/nature14098.html#supplementary-information> (2015).

Acknowledgements

Birgitte Simonsen is thanked for excellent technical help. This work was supported by Marie Curie Actions under the Seventh Frame Programme (Initial Training Network Grant TRAIN-ASAP, contract number 289285), the University of Copenhagen Centre for Control of Antibiotic Resistance (UC-Care) and the Augustinus Foundation, Bdr. Hartmanns Foundation and The Hørslev Foundation (PRH).

Author Contributions

I.G., A.E., B.J. N.M. and P.D. performed the experiments. I.G., A.E., B.J. N.M. A.O., P.D., L.G. and PRH conceived and designed the study. I.G., B.J. N.M., P.D. and P.R.H. wrote the manuscript. All authors contributed to the final version of the manuscript and approved it.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-019-39042-3>.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019